Treating Alzheimer’s Disease : Combine or Fail ?

  • Serge BakchineEmail author

Alzheimer’s disease (AD) is the most frequent neurodegenerative disease and accounts for more than 75% of cases of dementia in elderly people. Based on increasing life expectancy, it is predicted that the number of subjects suffering from AD and other dementias will reach the number of 131.5 millions worldwide in 2050 (1).

So far, only symptomatic treatments are available, that may ameliorate temporarily symptoms, but fail to provide any long-term efficacy. Despite major efforts and numerous trials, no disease-modifying drug (DMD) has demonstrated up today a benefit sufficient to obtain a marketing authorization from regulatory agencies. Moreover, since 2002, many candidate drugs encountered safety issues.

Facing these challenges, there is a need to rethink the strategies of therapeutic research in AD in order to propose innovative clinical trials that would enable more effective outcomes. In line with this momentum, the European Union-North American Clinical Trials in Alzheimer’s...


  1. 1.
  2. 2.
    Gauthier S, Molineovo J.L. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer’s disease. Alzheimer’s Dement. 2013, 9: 326–331.CrossRefGoogle Scholar
  3. 3.
    Cummings J, Lee G, Ritter A, Zhong K. Alzheimer’s disease drug development pipeline:2018. Alzheimer’s Dement Transl Res Clin Interv 2018;4:195–214.CrossRefGoogle Scholar
  4. 4.
    Tariot PN, Lopera F, Langbaum JB, Thomas RG, Hendrix S, Schneider LS, et al. The Alzheimer’s Prevention Initiative Autosomal-Dominant Alzheimer’s Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer’s disease, including a placebo-treated noncarrier cohort. Alzheimers’s Disease 2018;4:150–160.Google Scholar
  5. 5.
    Messmer MF, Wilhelm EE, Shoulson I. I-SPY 2 Breast Cancer Trial as a Model for Innovation in Alzheimer Disease Therapies. JAMA Neurol. 2017;74:1027–1028.CrossRefGoogle Scholar

Copyright information

© Serdi and Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Neurology department and Centre Mémoire Ressource et Recherche. CHU de ReimsUniversity of Reims-ChampagneReimsFrance

Personalised recommendations